Capreomycin, ethambutol and rifampicin. Clinical experience in Manchester.
D000636:Aminosalicylic Acids / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D004739:England; D004977:Ethambutol / Q000009:adverse effects*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007008:Hypokalemia / Q000139:chemically induced; D007538:Isoniazid / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced; D007759:Labyrinth Diseases / Q000139:chemically induced; D008274:Magnesium / Q000097:blood; D012293:Rifampin / Q000009:adverse effects*; D013307:Streptomycin / Q000009:adverse effects; D014786:Vision Disorders / Q000139:chemically induced; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000636:Aminosalicylic Acids; D000900:Anti-Bacterial Agents; D004977:Ethambutol; D008274:Magnesium; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin